Controller

Magnolia Medical Technologies • Seattle, Washington • Full Time

Posted on Fri, Jun 19, 2026

Controller

Magnolia Medical is an early stage, rapid growth commercial-stage medical device company with an opportunity for a Controller to join this team making a difference every day.  Magnolia Medical Technologies is developing solutions to challenges that have long plagued our healthcare system.

Our Steripath® Initial Specimen Diversion Device® for blood collection and contamination prevention has created a new standard of care for prevention of false-positive blood cultures, the gold standard diagnostic test for sepsis. Steripath delivers significant clinical and cost savings benefits which have been extensively proven with large bodies of clinical data and peer-reviewed published studies. Based on this exceptional performance profile, we have an exclusive FDA-cleared indication for reducing blood culture contamination and uniquely provide a money-back Clinical Performance Guarantee for Steripath to our hospital customers.

Position Description

The Controller is responsible for monthly close, financial reporting, overseeing the accounting department (currently 2 staff), maintaining accounting policies/procedures and other key roles in the accounting department. This role also provides analysis and insights to support fact-based decision making across the company.

The position reports to the Director of Finance and Accounting, and directly oversees two staff accountants, as well as any future hires in the accounting department. The accounting and finance departments are quickly expanding, and this role is critical to ensure alignment of policies and practices for all. This is an opportunity to shape and mature accounting processes in alignment with the company’s growth.

Responsibilities:

Required Experience and Qualifications:

About Magnolia Medical Technologies, Inc.

Magnolia Medical Technologies develops, manufactures and markets innovative blood and bodily fluidcollection devices to facilitate significant improvements in the accuracy, consistency and predictability of criticallaboratory tests.

Dr. Richard Patton, the company’s co-founder and Medical Director, invented and patented the Initial Specimen Diversion Technique (ISDT™) and Initial Specimen Diversion Device (ISDD®) for blood culture collection and contamination prevention, and authored the seminal peer-reviewed publication on this technique published in the Journal of Clinical Microbiology in 2010.

The company’s flagship product, Steripath® Initial Specimen Diversion Device® for blood culture collection and contamination prevention, has been clinically proven in 17 clinical studies including 5 peer-reviewed publications to virtually eliminate the preventable error of blood culture contamination and false positive results for the diagnosis of Sepsis – delivering a reduction in false positives of up to 92% with 12-month sustained contamination rates as low as 0.2% and an average annualized cost savings of $945,000.

Magnolia is establishing the new standard for blood culture integrity and sepsis testing accuracy with a mission to change national blood culture collection guidelines and contamination benchmarks.

The company has amassed an
intellectual property portfolio including more than 70 issued method, apparatus and design patents with more
than 50 additional patent applications pending.The total potential market for Magnolia’s technology exceeds $2.0 billion annually.

Magnolia Medical is committed to the continued development and successful marketing of innovative products that will transform the way healthcare is practiced around the world.  The company supports this effort by offering competitive compensation, incentive packages, benefits and career growth opportunities to the most qualified candidates in the marketplace. Magnolia Medical Technologies, Inc. is an equal opportunity employer.

For more information, visit magnolia-medical.com

View the interactive listing →